lfa-1

The Anti-CD11a/LFA-1α Antibody (R7-1) is a chimeric mouse IgG1 antibody specifically targeting human CD11a/LFA-1α. The recommended isotype control for this antibody is Mouse IgG1 kappa, Isotype Control.

Anti-Mouse CD11a/LFA-1α Antibody (M17/4) is a rat IgG2a kappa monoclonal antibody specifically targeting CD11a/LFA-1α in mouse models. The recommended isotype control for this antibody is 'Rat IgG2a kappa, Isotype Control'.

The Anti-LFA-1α/CD11a Antibody (TS-1/22.1.1.13) is a chimeric mouse IgG1 antibody targeting LFA-1α/CD11a of human origin. Its isotype control is designated as MouseIgG1kappa, Isotype Control.

XOMA-213 (LFA-102; X213) is a human monoclonal antibody (mAb) that specifically targets the PRLR/Prolactin Receptor. It inhibits hPRL-dependent growth of BaF3/hPRLR cells with an EC50 of 0.5 μg/mL. In models such as the Nb2-11-luc xenograft mouse and the DMBA-induced rat breast cancer model, XOMA-213 effectively suppresses PRLR signaling and tumor growth. This compound is applicable in research focused on breast cancer, hyperprolactinemia, and prostate cancer.

Efalizumab, a novel potent regulator of T cells, is a humanized LFA-1 α subunit (CD11a) monoclonal antibody. Efalizumab has inhibitory effects on T cell activation, skin T cell transport, and T cell adhesion to keratinocytes, and can be used to study plaque psoriasis and psoriatic arthritis.

Odulimomab (anti-LFA1), an anti-LFA-1 monoclonal antibody, inhibits T lymphocyte proliferation and provides protection against ischemia and reperfusion injury. It is utilized in researching transplant rejection and immunological diseases [1] [2].